Multidrug resistances and the failure of chemotherapies are often caused by the expression or overexpression of ATPbinding cassette transporter proteins such as the multidrug resistance protein, P-glycoprotein (P-gp). P-gp is expressed in the plasma membrane of many cell types and protects cells from accumulation of toxins. P-gp uses ATP hydrolysis to catalyze the transport of a broad range of mostly hydrophobic compounds across the plasma membrane and out of the cell. During cancer chemotherapy, the administration of therapeutics often selects for cells which overexpress P-gp, thereby creating populations of cancer cells resistant to a variety of chemically unrelated chemotherapeutics. The present study describes extremely high-throughput, massively parallel in silico ligand docking studies aimed at identifying reversible inhibitors of ATP hydrolysis that target the nucleotide-binding domains of P-gp. We used a structural model of human P-gp that we obtained from molecular dynamics experiments as the protein target for ligand docking. We employed a novel approach of subtractive docking experiments that identified ligands that bound predominantly to the nucleotidebinding domains but not the drug-binding domains of P-gp. Four compounds were found that inhibit ATP hydrolysis by P-gp. Using electron spin resonance spectroscopy, we showed that at least three of these compounds affected nucleotide binding to the transporter. These studies represent a successful proof of principle demonstrating the potential of targeted approaches for identifying specific inhibitors of P-gp.
Introduction
One long-standing problem of significant medical consequence in the chemotherapeutic treatment of cancer is multidrug resistance (MDR), which appears as either an acquired or inherent resistance to chemically diverse pharmaceuticals (Kartner and Ling, 1989; Ford and Hait, 1990; Harris and Hochhauser, 1992) . Although MDR can be caused by a number of different mechanisms (Binkhathlan and Lavasanifar, 2013) , it is often linked to the overexpression of P-glycoprotein (P-gp) Roninson et al., 1986; Gottesman and Pastan, 1993) . P-gp in humans is expressed from the multidrug resistance 1 gene (MDR1). As a member of the ATP-binding cassette (ABC) transporter family (subclass ABCB1), it exists as a plasma membrane protein of 1280 residues (Gottesman and Pastan, 1993; Persidis, 1999; Binkhathlan and Lavasanifar, 2013) . Three-dimensional structures of homologs of human P-gp from several bacterial species are known Locher, 2006, 2007; Ward et al., 2007) , as well as eukaryotic transporters from Caenorhabditis elegans (Jin et al., 2012) and Mus musculus (Aller et al., 2009; Li et al., 2014) . Most eukaryotic P-gps are monomeric and composed of two relatively symmetrical halves connected by a linker polypeptide. Each half is homologous to the homodimeric bacterial ABCB1 transporters (Chen et al., 1986) and possesses an N-terminal domain containing six transmembrane (TM) helices followed by a C-terminal nucleotide-binding domain (NBD) . Transport substrates appear to bind to multiple binding sites within the TM domains (Dey et al., 1997; Shapiro and Ling, 1997; Loo et al., 2003 Loo et al., , 2009 Lugo and Sharom, 2005) . The nucleotide-binding and the TM domains of P-gp and other ABC transporters appear to undergo very large conformational changes during the catalytic cycle (Hollenstein et al., 2007; Lee et al., 2008; Aller et al., 2009; Verhalen and Wilkens, 2011; Verhalen et al., 2012; Altenberg, 2013, 2014; Li et al., 2014) . Some of the structural models show tightly integrated, closed NBD dimers with nucleotides bound at each site while the TM domains are opened to the exterior of the cell Locher, 2006, 2007; Ward et al., 2007) . In nucleotide-free structures, the TM domains are opened to the interior of the cell with the NBDs disengaged and sometimes widely separated (Aller et al., 2009; Ward et al., 2007; Jin et al., 2012) . Molecular dynamics simulations of the MalK maltose transporter indicate that opening of the NBD dimer is a direct result of ATP hydrolysis at either nucleotide-binding site (Wen and Tajkhorshid, 2008) . Targeted molecular dynamics studies of human P-gp based on crystal structures of homologs in various conformations visualized the large, concerted conformational changes required for a catalytic transport cycle (Wise, 2012) . P-gp has been actively investigated as a pharmacologic target in MDR cancers for several decades. P-gp inhibitors have been classified into three generations of compounds (Binkhathlan and Lavasanifar, 2013) . Generation 1 included compounds already approved as therapeutics for other indications, including verapamil, quinine, quinidine, and cyclosporine A. These agents failed at clinically reversing MDR because the high concentrations required to inhibit P-gp resulted in unacceptable side effects (Palmeira et al., 2012) . The secondgeneration compounds were more effective, but many of these compounds, like the first-generation compounds, were transport substrates for P-gp, requiring relatively high concentrations. Some also affected cytochrome P450 CYP3A isozymes, altering the pharmacokinetics of other drugs (Binkhathlan and Lavasanifar, 2013) . The best of the third-generation P-gp inhibitors appears to be tariquidar (Stewart et al., 2000; Walker et al., 2004) . However, ongoing clinical trials of tariquidar and other inhibitors have reported only limited successes in reversing MDR (Binkhathlan and Lavasanifar, 2013) .
Here, we report efforts aimed at identifying novel inhibitors of P-gp that might be useful as lead compounds for reversing MDR in cancers. We employed very high-throughput, massively parallel computational screens of a very large database of drug-like structures (Irwin and Shoichet, 2005; Irwin et al., 2012) to one hypothetically critical conformation of P-gp, a partially opened outward structure described previously (Wise, 2012) . Our present study identifies potential inhibitors that specifically target the NBDs of P-gp with limited interactions at the drug-binding sites. We hypothesized that compounds that strongly bind to the power-transducing structures of P-gp but not well to the drug-pumping structures would potentially inhibit P-gp catalyzed transport without being transported out of the cell. Drug-like compounds with these attributes may make good cotherapeutic leads to be developed against MDR in cancer chemotherapies.
Materials and Methods
In Silico Screening. A database of commercially available compounds that includes molecules with "clean" drug-like characteristics was obtained from the ZINC Web site (http://zinc.docking.org/) (Irwin and Shoichet, 2005; Irwin et al., 2012) , and about half these compounds (5,277,160) were used for in silico docking experiments with a human P-gp structural conformation as described earlier (Wise, 2012) . The modeled protein conformation represents a conformation of P-gp where the NBDs are fully engaged similar to those of the Sav1866 crystal structure (Dawson and Locher, 2006) . Nucleotides were removed from the protein before docking studies were performed. Ligand docking used the Autodock 4.2 program (http:// autodock.scripps.edu/) Morris et al., 1996; Osterberg et al., 2002) and the high-performance computational facilities of the Center for Scientific Computing at Southern Methodist University. Ligands were converted to pdbqt file format using the AutoDockTools Python scripts (Morris et al., 2009) . Autodock parameters included 100 Lamarckian genetic algorithm runs per ligand with mutation rates of 0.02, crossover set at 0.8, and a population size of 300, with 3,000,000 evaluations and 27,000 generations per tested ligand. Roughly 5 million of these docking studies against the P-gp NBDs were analyzed in the first round of the in silico screening experiments.
As a second part to the experiment, docking against the drugbinding domains (DBD) of the same P-gp structure was performed. This experiment used two overlapping grid maps that encompassed the entire P-gp molecule minus the NBDs. Two grids were required because of the size of the desired zone. A subset of ligands that was found to dock to P-gp with estimated binding affinities of less than 200 nM at the NBD was used in the secondary docking experiments to the DBDs. Only ligands predicted to bind the NBD at least 100-fold more tightly than the DBD were considered for further analysis.
ATP Hydrolysis Assays. A well-established activity assay for ATP hydrolyzing enzymes (Delannoy et al., 2005; Hoffman et al., 2010) was used that couples the hydrolysis of ATP by P-gp to the oxidation of NADH to NAD 1 through the reactions of pyruvate kinase and lactate dehydrogenase (Vogel and Steinhart, 1976) . These reactions were adapted to medium-throughput conditions on 96-well plates. To test the effects of the in silico identified potential inhibitors, a total volume of 5 ml of various concentrations of experimental compounds dissolved in dimethylsulfoxide (DMSO) was added to the wells in a 96-well plate containing 45ml of equilibration buffer (20% glycerol, 50 mM Tris-Cl, pH 7.5). To each of these wells, 50 ml of a solution containing 80-100 mg/ml lipid-activated, concentrated P-gp (see below) in equilibration buffer in the absence or presence of 300 mM verapamil (dissolved in water) was added.
After incubating the plate for 30 minutes at 37°C, we added to each well 100 ml coupled enzyme assay cocktail (50 mM Tris-Cl, pH 7.5, 24 mM MgSO 4 , 20 mM KCl, 2 mM PEP, 0.014 mg/ml pyruvate kinase, 0.0288 mg/ml lactate dehydrogenase, 1.13 mM NADH, and 4 mM ATP), prewarmed to 37°C. Immediately after this addition, ATPase activity was assayed for 20-30 minutes. ATP hydrolysis was recorded as the absorbance decrease at 340 nm using a BioTek Eon plate reader (BioTek, Winooski, VT). An extinction coefficient for NADH of 6300 M 21 cm 21 was used. All assays were performed in duplicate or triplicate and were repeated at least two times using different P-gp preparations. Control experiments were performed that showed that none of the identified inhibitors affected the other enzymes in the coupling assays. Dose response curves and inhibitor concentration values (IC 20 , IC 50 , and IC 80 values) were calculated from the data as described by Copeland (Copeland, 2000 (Copeland, , 2013 using a four-parameter logistic fit.
Lipid Activation. To stabilize the protein for the ATP hydrolysis assays, lipid activation of the purified P-gp was performed. Lipid stocks were prepared from L-a-phosphatidyl-choline from soybean (∼40%) (Sigma-Aldrich, St. Louis, MO) by adding lipid stock buffer (50 mM Tris-Cl, pH 7.5, 0.1 mM EGTA) to solid lipid in glass test tubes. Lipid stock concentrations were 25 mg/ml or 100 mg lipid/ml buffer. The suspension was flushed with argon and subsequently sonicated in a bath sonicator at room temperature for 15-30 minutes until the mixture clarified. The lipid suspension was supplemented with 2 mM dithiothreitol and stored at 4°C under argon until use. To activate the P-gp, we prewarmed lipid stock to 37°C, mixed with concentrated protein (see below) at a ratio of 2:1 (w/w) and then diluted with equilibration buffer at 37°C to a final concentration of typically 100 mg P-gp per ml activated P-gp mix. This mixture was incubated at room temperature for 30 minutes to 1 hour before use in the coupled enzyme assays.
Preparation of Isolated P-gp. The P-gp used in these assays was a close relative of the human P-gp that is found in Mus musculus (MDR3, 87% identical to human P-gp). A mutant form of the mouse Identification of Targeted P-Glycoprotein Inhibitors P-gp where all intrinsic cysteine amino acids had been replaced by alanine residues was recombinantly expressed in the yeast Pichia pastoris (Lerner-Marmarosh et al., 1999; Tombline et al., 2006) . This cysteine-less mouse P-gp was used for assaying the potential inhibitor compounds. Purification of the protein was performed essentially as described by Delannoy et al. (2005) with small modifications resulting in highly enriched P-gp in mixed micelles containing dodecyl maltoside and lysophosphatidyl choline. To obtain concentrated P-gp, the elution fraction of the Ni-NTA column was concentrated 70-to 100-fold using Amicon Ultra centrifugal filters (Amicon/Millipore Corp., Billerica, MA) with a molecular mass cutoff of 100,000 Da. This procedure enriches both protein and micelles and ensures retained solubilization of the membrane protein.
Electron Spin Resonance Measurements. All electron spin resonance (ESR) spectroscopy measurements were performed using a Bruker EMX 6/1 ESR spectrophotometer (Bruker, Karlsruhe, Germany) operating in X-band mode and equipped with a high-sensitivity cavity, as described previously (Delannoy et al., 2005) . Briefly, a total of 30-40 ml of sample was pipetted into 50-ml glass capillaries. The top of the capillary was closed and inserted into a quartz cuvette. ESR spectra were acquired at a microwave frequency of 9.33 GHz, microwave power of 12.63 mW, 100 kHz modulation frequency, and a resolution of 1024 points. The center field of the scan was at 3325 G, and an area of 100 G was scanned with a peak-to-peak modulation amplitude of 1 G. The time constant was set to 10.240 milliseconds, and the conversion time to 163.84 milliseconds, resulting in a total time sweep of 167.772 seconds. The signal gain was adjusted for the spin-labeled (SL)-ATP concentrations in the different experiments.
All samples in the ESR experiments were dissolved in buffer containing 50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 20% glycerol, 0.1% dodecyl maltoside, 0.01% lysophosphatidyl choline, and 300 mM imidazole with or without the experimental inhibitor compounds present. All ESR measurements were at room temperature. Titration experiments were performed using increasing concentrations of 2939-SL-ATP, essentially as described in Delannoy et al. (2005) . SL-ATP is a substrate of P-gp and is hydrolyzed to the corresponding SL-ADP by the enzyme (Delannoy et al., 2005) . Due to this fact, the phosphorylation state of the spin-labeled nucleotide is not known throughout the course of an experiment. The spin-labeled nucleotide is therefore referred to as SL-ANP. The amount of protein-bound SL-ANP was determined as the difference between the known total concentration of SL-ATP added and the free spin-labeled nucleotide observed in the experiment. The latter was measured by comparing the amplitude of the high field ESR signal of SL-ANP at each point to a standard curve of SL-ATP generated in the absence of protein.
The amplitudes of the high-field signals were determined using WINEPR (Bruker) software for each concentration of SL-ATP used. Moles of SL-ANP bound per mole of P-gp were plotted over the free SL-ANP concentration, and nonlinear, hyperbolic curve fitting of the results was performed using Origin 8.5.1 (OriginLab, Northampton, MA) to determine the maximum binding and apparent affinity for the spin-labeled nucleotide. The equation used for fitting the curves was y 5 P1 * x/(P2 1 x), where P1 corresponds to the maximum binding of SL-ANP (moles of SL-ANP bound per mole P-gp), and P2 equals the apparent dissociation constant for SL-ANP. The P-gp concentrations in titration experiments ranged from 20 to 100 mM in the presence of 2 mM MgSO 4 , 150 mM verapamil, and 0, 25, 50, or 100 mM of experimental compound dissolved in DMSO. For the experiments shown in Fig. 4 , the starting concentration of P-gp was 50 mM and the concentration of inhibitor was as given in the figure legend. The final volume of the assay was 40 ml. Between three and five individual titration experiments were performed for each compound and concentration using at least two different enzyme preparations. The concentration of SL-ATP ranged from 25 to 500 mM.
Chemicals. Potential inhibitors of P-gp identified through in silico screening were purchased in small quantities through SIA MolPort (Riga, Latvia). Dodecyl maltoside was purchased from Inalco Pharmaceuticals (San Luis Obispo, CA). Lysophosphatidyl choline was a generous gift from Lipoid GmbH (Ludwigshafen, Germany).
Results
Targeted In Silico Screening for Inhibitors of Human P-gp Using a Large Database of Drug-like Small Molecules. The goal of this study was to identify inhibitors of P-gp that interrupt ATP-binding to or hydrolysis by P-gp by interacting at the NBDs of P-gp. Using targeted molecular dynamics techniques, we previously visualized structural changes in human P-gp as the transporter transitions from one conformational state to another during a catalytic transport cycle (Wise, 2012) . In the present study, we chose one conformation of P-gp for docking analysis that corresponded to a structural conformation of P-gp where the NBDs are fully engaged and the DBDs are partially opened outward. This P-gp conformation, which is similar to that observed in the crystal structural model of the bacterial Sav1866 ABC transporter (Dawson and Locher, 2006) , was used as the protein target because it possesses fully formed adenine nucleotide-binding sites. We hypothesized that compounds that interfere with nucleotide binding to P-gp or that disrupt the nucleotide binding sites might make good inhibitors of ATP binding or hydrolysis and thus be inhibitors of drug transport.
Irwin and Shoichet have made publicly available a computational resource containing the three-dimensional coordinates of over 20 million commercially obtainable compounds, including subsets that possess the chemical characteristics often found in approved medicinal drugs (see the ZINC database at http://zinc.docking.org/) (Irwin and Shoichet, 2005; Irwin et al., 2012) . In the first round of docking, about 5.3 million out of about 11 million of these drug-like molecules (subset 13 of the ZINC database) were individually tested for binding interactions at the NBDs of human P-gp using the AutoDock4.2 program (Morris et al., 2009) , as described in Materials and Methods. The results of these calculations were subsequently analyzed for the estimated binding affinity of the ligands to P-gp. Compounds were identified that were predicted to have potentially strong binding interactions at the P-gp NBD structures. We disregarded any compounds for further study that had predicted estimated K d values that were more than 200 nM.
This first set of 180,142 putative P-gp ligands that possessed predicted affinities to the NBDs of P-gp of at least 200 nM (subset 1) was further analyzed for possible interaction at the DBDs of P-gp in a second round of docking experiments that targeted the transport drug binding sites of P-gp. Ultimately, compounds that interacted strongly at NBDs but weakly at the DBDs of P-gp were sought. The docking results for subset 1 compounds at either of two target grids at the DBD of P-gp (see Materials and Methods) were therefore analyzed for predicted binding affinities at the drug-binding sites. The calculated affinities at the NBDs and the DBDs of P-gp were then compared for each compound in subset 1.
Those molecules with estimated K d values at the DBD of P-gp that were $100 times that of the projected K d at the NBDs (subset 2) were considered to be potential inhibitor candidates for P-gp that specifically target the NBDs of P-gp. Subset 2 consisted of approximately 250 molecules. Of these initial computational leads, 35 compounds were purchased from commercial sources (numbered 11-45) and used in in vitro biochemical assays to determine their effectiveness in inhibiting ATP-hydrolysis by isolated P-gp. These 35 compounds were representative of the various binding clusters observed in silico both within and outside the nucleotidebinding sites on P-gp.
Screening for ATP Hydrolysis Inhibition by In Silico Identified Putative P-gp Inhibitors. The ability of the molecules identified using in silico methods to function as potential inhibitors of P-gp was tested by assessing their capability to inhibit ATP hydrolysis using purified P-gp. ATP hydrolysis by P-gp is stimulated by transport substrates such as the calcium channel blocker verapamil. Verapamil has been found to inhibit P-gp catalyzed transport by competing for transport cycles (reviewed in Palmeira et al., 2012) . Depending on whether a transport substrate such as verapamil is present in the assay, purified P-gp preparations exhibit ATP hydrolysis rates that vary over a range from about 50 nmol min 21 mg 21 (basal activity) to about 750-1000 nmol min 21 mg 21 (stimulated activity). In our initial screening of the in silico-generated hits of subset 2, we tested the effect on basal ATP hydrolysis activity (inhibition and or stimulation) of the commercially available compounds chosen from subset 2 in assays not containing verapamil. Compounds that stimulated the basal activity of P-gp in the absence of verapamil were assumed to achieve the stimulation by binding to the drug-binding sites of P-gp similar to transport substrates such as verapamil and would therefore not support our premise of finding compounds that specifically interact with the NBDs and not the DBDs. Several of the compounds tested did indeed stimulate basal rates of hydrolysis by P-gp a factor of 1.5 or more (data not shown) and were not further pursued in this work. Only compounds that in addition to stimulating basal activity also showed strong inhibition of stimulated activity were further pursued in this study.
To test the ability of the selected subset 2 compounds to inhibit verapamil-stimulated ATP hydrolysis activities of P-gp, verapamil was added at 150 mM final concentration to assays containing purified P-gp. ATP hydrolysis was determined at near physiologic ATP concentrations (2 mM ATP). Figure 1A (Fig. 1A) . Compounds that did not show significant inhibition of ATP hydrolysis in these assays were not further considered. A side-by-side comparison of verapamil-stimulated and basal ATP hydrolysis assays in the presence of the four confirmed inhibitors of P-gp is presented in Fig. 1B . The figure shows that under the conditions used (i.e., in the presence of 2 mM ATP) all compounds inhibited both basal (Fig. 1B, gray bars) and stimulated (Fig. 1B, black bars) ATPase activities. In all cases, the stimulated ATP hydrolysis rate was more strongly affected by the compounds.
The structures of the four targeted inhibitors of P-gp ATP hydrolysis activity are shown in Fig. 2 . It should be noted that both compounds 34 and 45 were used as racemic mixtures of the respective enantiomeric compounds.
Dose Response Testing of Identified P-gp Inhibitors. The four identified P-gp inhibitors were investigated further in ATP hydrolysis dose-response inhibition curves. Figure 3 shows the verapamil-stimulated ATP hydrolysis activities of P-gp preparations in the presence of varying concentrations of inhibitor compounds after normalizing to verapamil-stimulated P-gp activity measured in the absence of inhibitor. The IC 20 , IC 50 , and IC 80 inhibition values were calculated as described in Materials and Methods for the inhibitors in these assays, and the results of these calculations are presented in Table 1 . IC 50 values in the range of 10 25 M were observed for all four P-gp inhibitors in these experiments.
Probing Inhibition Mechanisms of Identified P-gp Inhibitors Using ESR Spectroscopy and Spin-Labeled ATP. The possible mechanism of inhibition of ATP hydrolysis by the identified P-gp inhibitors was investigated as in Delannoy et al. (2005) by measuring the maximal binding stoichiometry and binding affinity of an analog of ATP, SL-ATP, to P-gp both in the presence and absence of the identified inhibitors. These methods allowed us to directly follow binding of SL-nucleotide to P-gp under equilibrium binding conditions. Because SL-ATP is a substrate for P-gp catalyzed ATP hydrolysis (Delannoy et al., 2005) , both SL-ATP and SL-ADP can potentially bind to P-gp. We therefore refer to the spin-labeled nucleotide in these experiments as SL-ANP.
ESR spectra were acquired for known concentrations of SL-ATP and compared with spectra acquired in the presence of known concentrations of P-gp, verapamil, and the different inhibitor molecules. Free, not-enzyme-bound, SL-ANP results in ESR spectra with three relatively sharp, equidistant signals (see Fig. 4A ). The high-field signal of the free SL-ANP can be seen as the sharp signal on the right. The relatively broad signals of the enzyme-bound spin-labeled nucleotide can be seen to the left (low field) and right (high field) of the three signals resulting from the free SL-ANP. The signal gain was increased for better visualization of SL-ANP bound to P-gp. The high-field signal of the freely mobile, unbound SL-ANP was used to calculate the amount of free SL-ANP-analog in the binding assays with P-gp (Materials and Methods) (Fig. 4A) . The amount of P-gp-bound SL-nucleotide was then calculated as the difference between the known amount of total SL-ATP added and the measured free SL-ANP, using a standard curve of increasing amounts of SL-ATP as a reference (see Materials and Methods) (Delannoy et al., 2005) . The results of SL-ANP binding experiments to P-gp in the absence or presence of P-gp inhibitors are presented in Fig. 4 , B-F.
In the absence of drug, but in the presence of 5% (v/v) drug vehicle DMSO, maximum binding to P-gp was found to extrapolate to 2.2 6 0.2 mol SL-ANP bound per mol of P-gp with an apparent K d of 88 6 21.6 mM (Fig. 4B) . SL-ATP titrations in the presence of experimental drug-like compounds were all compared with standard curves generated in the presence of 5% DMSO and the experimental compound to control for potential compound-SL-ATP interactions. In an Identification of Targeted P-Glycoprotein Inhibitors initial set of titrations, stoichiometric amounts of about 50 mM P-gp and 50 mM experimental compounds were mixed, and increasing amounts of SL-ATP were added (Fig. 4, C-F) . Compounds 19 and 45 significantly decreased the stoichiometry of SL-nucleotide binding under these conditions to approximately 1 or 0.6 mol/mol, respectively (see Fig. 4 , C and F). These compounds also caused a decrease of the apparent K d of P-gp for SL-ANP binding to about 20 mM. Compounds 29 and 34 did not show an obvious change in maximal nucleotide binding or the apparent dissociation constants for SL-ANP when incubated with P-gp at 50 mM (Fig. 4, D 
and E).
When titrations were performed in the presence of 100 mM of compound 34, however, maximum binding of SL-ANP to P-gp was decreased to 0.8 mol/mol, while the dissociation constant for SL-ANP binding did not change significantly (Fig. 4E, insert) . Titrations in the presence of 100 mM of compound 45 were not significantly different from those in the presence of 50 mM of compound 45 (not shown). However, when the concentration of compound 45 was decreased to 25 mM while P-gp remained at 50 mM, maximal binding of about 1.3 moles SL-ANP/mol of P-gp was observed (Fig. 4F, insert) , again with decreased apparent K d . Compound 29 did not significantly affect SL-nucleotide binding at either 50 mM or 100 mM concentration.
Comparing Success Rates to Other Methods. Schmidt et al. (2007 Schmidt et al. ( , 2008 reported in two studies that a series of dioxolane-derivatized piperazines and several phenothiazines and related compounds resensitized drug-resistant colon cancer or porcine kidney epithelial cells to vincristine. The cell lines used in these studies were shown to stably express P-gp at moderately high-expression levels. We took 10 of the best compounds identified in (Schmidt et al., 2007 (Schmidt et al., , 2008 and assayed them for their effect on ATP hydrolysis by P-gp as if they had passed our docking criteria, although none of them actually did pass these computational criteria (not shown). One of the 10 compounds was observed to moderately inhibit ATPase activity of P-gp, but ESR titrations as described earlier did not indicate any interaction of the compound with the NBD (not shown), indicating that inhibition of P-gp ATP hydrolysis was not caused by binding to or close to the nucleotide binding sites. The hit rate for this quantitative structure activity relationships cell culture resensitization selection method (1 in 10) compares favorably with our computational hit rate (4 in 35) of ATP hydrolysis inhibitors, where three of the four identified inhibitors adversely affected SL-nucleotide binding to P-gp. This comparison shows that the computational selection method used in this work was at least as good as the quantitative structure activity relationships cell culturing system in identifying inhibitors of ATPase by P-gp and was arguably better at targeting these inhibitors to the NBDs of P-gp.
Discussion
Screening for Inhibitors Targeted to the NucleotideBinding Domains of P-gp. Our goal was to identify inhibitors of P-gp that interrupt ATP-binding or hydrolysis by interacting at the NBDs of P-gp. We employed a structural homology model of a conformation of human P-gp that possesses fully formed nucleotide-binding sites that are similar to those observed in the crystal structure of the bacterial Sav1866 ABC transporter (Dawson and Locher, 2006) . In this conformation, the Sav1866 transporter bound both ADP and AMPPNP [59-adenylyl-b,g-imidodiphosphate] Locher, 2006, 2007) . To identify drug-like molecules that interact strongly at the NBDs of P-gp, we targeted the entire composite of the N-terminal and C-terminal NBDs of P-gp in massively parallel in silico docking experiments. A large set of drug-like molecules (∼11 million compounds) was obtained from the ZINC chemical database, and about half of these were employed in docking calculations. A subset of ∼180,000 molecules was identified that was predicted to interact with the NDBs of P-gp with estimated affinities less than 200 nM. It should be noted that the ATP-binding sites in Each plot represents the composite results of three to five individual experiments performed on at least three independently isolated P-gp preparations. ATPase activity was determined at 2 mM MgATP as described in Materials and Methods. The curves shown were calculated as described in Materials and Methods using a four-parameter logistic fit as described in Copeland (2000 Copeland ( , 2013 . 7 6 1.6 27 6 6.8 108 6 47.0 Compound 34 3 6 0.7 9 6 1.4 24 6 6.0 Compound 45 10 6 1.5 18 6 1.5 32 6 4.6
Identification of Targeted P-Glycoprotein Inhibitors the protein structure were left unoccupied and freely available for docking in these experiments. In a secondary screen, this subset 1 of identified molecules was docked to the DBDs of P-gp using the same programs. A much smaller subset of about 250 compounds was identified that was predicted to bind weakly at the DBDs but have high-affinity interactions at the NBDs. These criteria were deemed prognostic of putative P-gp inhibitor molecules that may interfere with ATP use by P-gp while not being transport substrates of the pump. Screening In Silico Hits Using ATP Hydrolysis Assays. From the approximately 250 compounds that were predicted to bind tightly at the NBDs and significantly less strongly at the DBDs of P-gp, 35 were analyzed in biochemical assays using isolated P-gp for effects on basal or transport substrate stimulated rates of ATP hydrolysis. We expected that compounds that interacted with the DBDs of P-gp despite AutoDock predictions to the contrary might stimulate the basal ATP hydrolysis rates similar to other transport substrates. Compounds that did stimulate basal rates over 1.5-fold were therefore not considered further.
Four compounds, 19, 29, 34, and 45, showed significant inhibition of verapamil-stimulated ATP hydrolysis activities when assayed at 25 mM both at high ATP (10 mM, not shown) and near physiologic ATP concentration (2 mM ATP, Fig. 1, A and B). The structural formulas for these four compounds are shown in Fig. 2 . Compounds 29 and 34 cause slight activations of basal ATPase activity rates of P-gp when assayed at 10 mM ATP (not shown), indicating that these compounds may interact with the DBDs of P-gp to some degree. Compounds 19 and 45 did not stimulate basal hydrolysis rates at either ATP concentration, suggesting that these compounds do not productively interact with the DBDs or that the net effect of interaction at these or other sites is to inhibit P-gp catalyzed ATP hydrolysis.
It is interesting to note that transport-drug-stimulated ATP hydrolysis was much more affected by the four inhibitor compounds than basal activity (see Fig. 1B ). One possible explanation for this observation may be that the compounds tested were selected for binding to NBDs in their closed conformation, which corresponds to the formation of complete nucleotide-binding sites Locher, 2006, 2007) . It seems feasible that in a transport-drug-stimulated state, more of the enzyme adopts the closed NBD conformation and is thus more susceptible to binding of and being inhibited by the inhibitor candidates than enzymes performing only basal level hydrolysis. In addition, previous results from our group showed that binding of transport substrate indeed altered the conformation of the nucleotide-binding sites (Delannoy, 2005; Hoffman, Wise and Vogel, unpublished data) . This again may cause better binding of the inhibitor molecules to the NBDs.
Dose-Response Curves. In further tests using isolated P-gp preparations, the inhibitor concentrations in verapamilstimulated ATP hydrolysis assays were varied, and the residual activities were monitored. Figure 3 shows the results of these assays for the four inhibitor compounds. Affinities as expressed through IC 50 values ranged from 9 to 27 mM for the four inhibitors (Table 1) . These values are high but were deemed appropriate for initial screening hits. Lead optimization studies are in progress to lower these IC 50 values to a more useful pharmacologic range.
Mechanisms of Inhibition by the Four Identified Inhibitors. In a series of experiments designed to elucidate whether the four inhibitors indeed interacted with the NBDs of P-gp, spin-labeled analogs of ATP were used in equilibrium binding studies to determine whether the compounds affected ATP binding to P-gp. These studies take advantage of the fact that protein-bound SL-ANP and free SL-ANP have different, well-resolved ESR spectra that enable the assessment of binding of the analog under equilibrium conditions. The measured maximum binding was in good agreement with values previously reported by us (Delannoy et al., 2005) and others (Qu et al., 2003) . The difference between the previously reported K d of P-gp for SL-ANP in the presence of verapamil of 180 mM (Delannoy et al., 2005) and the K d reported in this article may be due to the presence of DMSO and/or the somewhat improved purity of the protein.
Inclusion of compounds 19 or 45 at concentrations equimolar to protein (about 50 mM) resulted in maximum binding of about 1 mol/mol SL-ANP in the presence of compound 19 and of about 0.5 mol/mol in the presence of the same concentration of compound 45. The apparent K d was decreased to about 20 mM in the presence of either compound. Lowering of the number of accessible nucleotide-binding sites in addition to lowering of the dissociation constant for nucleotide binding strongly suggests that these two inhibitors are directly affecting the ATP binding sites of P-gp. Earlier studies have shown that it is possible to inhibit ATP hydrolysis by P-gp by abolishing function at a single NBD (e.g., Urbatsch et al., 1998 Urbatsch et al., , 2003 . Such "half-site reactivity" might be expected from agents that interact strongly at one of the nucleotide-binding sites of P-gp. In earlier experiments, we observed that SL-ANP binding to The location of nucleotide bound to the human P-gp model used for docking is shown. Note that nucleotides were removed from the model before docking was performed. For orientation, the catalytic glutamate residues E556 and E1201 are located on the right and left sides of the representation, respectively. Right: The approximate locations of the highest affinity interaction predicted by docking studies for the four identified inhibitors of P-gp are shown relative to the protein structure. Both compounds 19 and 45 bound to the E556-binding site are superposed in the representation. The figure shows that three of the four identified inhibitors (19, 34, and 45) are bound in the nucleotidebinding sites. These are the same compounds that altered ATP binding in the ESR titration experiments described. Compound 29 was predicted to bind outside the nucleotide-binding sites in the docking experiments. This compound did not alter the binding characteristics of SL-ATP at the concentrations used for the experiments reported here. Residues within 5 Å of the putative docking clusters of the inhibitor molecules are presented in Table 2 .
Identification of Targeted P-Glycoprotein Inhibitors vanadate-inhibited P-gp was reduced to about 1 mol/mol and also exhibited a decreased K d for SL-ANP binding (Delannoy, unpublished data) . The fact that binding of SL-ANP was reduced to less than 1 mol/mol in the presence of equimolar concentration of compound 45 may be explained by a strong interaction of compound 45 with P-gp that affects binding to both nucleotidebinding sites. Because the K d for SL-ANP and compound 45 are within the same overall range, we speculate that in equilibrium a subset of the protein molecules has no inhibitor bound and is therefore able to bind the nucleotide. The number of accessible nucleotide binding sites did not further decrease when the concentration of compound 45 was increased to 100 mM, but about doubled when the compound 45 concentration was reduced to 25 mM. Because compound 45 was obtained as a racemic mixture of the two enantiomers, these results suggest that both enantiomers actively interact with the P-gp NBDs At equimolar inhibitor and transporter concentrations, no effect on the stoichiometry of nucleotide binding was observed with inhibitor 34. When the concentration of 34 was doubled to 100 mM, however, reduced binding of about one mol/mol SL-ANP was observed. This may indicate that two molecules of compound 34 are needed to interact with each molecule of P-gp to exert its inhibitory effect. Alternatively, because compound 34 was also obtained as a racemic mixture, this result may be explained with only one of the stereoisomers binding to the protein and affecting nucleotide accessibility of the nucleotide-binding sites.
Compound 29 did not affect the binding stoichiometry in these tests nor did it significantly affect the K d for SL-ANP at any concentration tested, suggesting that compound 29 did not directly interact with the P-gp nucleotide binding sites but may cause inhibition of ATP-hydrolysis by blocking crucial conformational transitions of the enzyme.
Correlation of the Best Docking Pose of the Inhibitors with Effects on Nucleotide Binding. It is remarkable that the highest affinity docking pose shown for each of the four identified P-gp inhibitors correlates very well with the effect these inhibitors have on SL-ANP binding to P-gp. Compounds 19, 34, and 45 reduced SL-ANP binding by at least 1 mol/mol, and the best docks for these inhibitors are directly at the nucleotide-binding sites (Fig. 5) . The fact that compound 34 needed to be in 2-fold excess over protein to affect nucleotide binding may be due to the fact that a racemic mixture of the compound was used. Conversely, compound 29 neither affected the stoichiometry nor the affinity of P-gp for SL-ANP, and its best dock is found between the two NBDs of P-gp and not directly within the nucleotide-binding sites (Fig. 5) . This direct correlation of the best docking modes of the inhibitors to the possible mechanism of inhibition by the inhibitors was unanticipated. Other groups have shown that flavonoids are strong modulators of P-gp activity and that they interact with the NBDs of the enzyme (Di Pietro et al., 2002) . It is of interest to point out that one of the inhibitors identified here, compound 19, contains both the A and C rings of flavinols with a modification of the B ring (Fig. 3) . Compound 19 may therefore be considered a flavonol analog. Comparison of the binding modality of 19 with those of flavonoids reported in Badhan and Penny (2006) shows that the modified B ring of 19 is in close contact with the tyrosine of the A-loop (Y401 in our study; Y1044 in the Badhan and Penny study), very similar to the B-rings of flavonoids studied by Badhan and Penny (2006) .
Conclusion
The present study demonstrates that high-throughput in silico docking studies can be used to generate inhibitor leads that target specific areas within ABC transporters responsible for MDR in cancer chemotherapies. The novel "subtractive" screening methods employed here that target one section of the protein and deemphasize binding at a different section of the protein may be generalizable. Although exploratory in nature, the presented study yielded productive leads for both catalytic sites and an allosteric site inhibitors. These inhibitor-binding sites are now being investigated more thoroughly in current experiments. We are also expanding the docking selections to other conformations of P-gp from the targeted molecular dynamics trajectories. This approach, pioneered by McCammon and colleagues (Amaro et al., 2008) , adds a protein dynamic component to docking studies such as presented here.
It is easy to foresee the use of similar subtractive screening methods applied to other difficult drug discovery projects that may generate sets of drug leads that discriminate between desired drug targets and other proteins that should be excluded from interactions with the leads. Optimization studies to increase the affinities of the P-gp inhibitors identified in these studies are currently in progress.
